scholarly journals IL-6, IL-8 and TNF-α levels correlate with disease stage in breast cancer patients

2017 ◽  
Vol 26 (3) ◽  
pp. 421-426 ◽  
Author(s):  
Yunfeng Ma ◽  
Yi Ren ◽  
Zhi-Jun Dai ◽  
Cai-Jun Wu ◽  
Yan-Hong Ji ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Disease Stage ◽  
Breast Cancer Patients ◽  
Tnf Α

scholarly journals Glutathione S-transferase M1 (GSTM1) and T1 (GSTT1) variants and breast cancer risk in Burkina Faso

2019 ◽  
Vol 10 (1) ◽  
pp. 175-183 ◽  
Author(s):  
Isabelle Touwendpoulimdé Kiendrebeogo ◽  
Abdou Azaque Zoure ◽  
Pegdwendé Abel Sorgho ◽  
Albert Théophane Yonli ◽  
Florencia Wendkuuni Djigma ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Cancer Patients ◽  
Sporadic Breast Cancer ◽  
Disease Stage ◽  
Breast Cancer Patients ◽  
Glutathione S Transferase ◽  
Increased Risk ◽  
Increased Susceptibility

AbstractBackground and objectiveBreast cancer remains the most common cause of cancer mortality in women. The aim of this study was to investigate associations between genetic variability in GSTM1 and GSTT1 and susceptibility to breast cancer.MethodsGenomic DNA was extracted from blood samples for 80 cases of histologically diagnosed breast cancer and 100 control subjects. Genotyping analyses were performed by PCR-based methods. Associations between specific genotypes and the development of breast cancer were examined using logistic regression to calculate odds ratios [1] and 95% confidence intervals (95%CI).ResultsNo correlation was found between GSTM1-null and breast cancer (OR = 1.83; 95%CI 0.90-3.71; p = 0.10), while GSTT1-null (OR = 2.42; 95%CI 1.17-5.02; p= 0.01) was associated with increased breast cancer risk. The GSTM1/GSTT1 double null was not associated with an increased risk of developing breast cancer (OR = 2.52; 95%CI 0.75-8.45; p = 0.20). Furthermore, analysis found no association between GSTM1-null (OR =1.12; 95%CI 0.08-15.50; p = 1.00) or GSTT1-null (OR = 1.71; 95%CI 0.13-22.51; p = 1.00) and the disease stage of familial breast cancer patients or sporadic breast cancer patients (GSTM1 (OR = 0.40; 95%CI 0.12-1.32; p = 0.20) and GSTT1 (OR = 1.41; 95%CI 0.39-5.12; p = 0.75)). Also, body mass index (BMI) was not associated with increased or decreased breast cancer risk in either GSTM1-null (OR = 0.60; 95%CI 0.21-1.68; p = 0.44) or GSTT1-null (OR = 0.60; 95%CI 0.21-1.68; p =0.45).ConclusionOur results suggest that only GSTT1-null is associated with increased susceptibility to breast cancer development.

scholarly journals Report of clinico-pathological features of breast cancer in HIV-infected and uninfected women in Botswana

2019 ◽  
Vol 14 (1) ◽  
Author(s):  
Rohini K. Bhatia ◽  
Mohan Narasimhamurthy ◽  
Yehoda M. Martei ◽  
Pooja Prabhakar ◽  
Jeré Hutson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Stage Iii ◽  
Disease Stage ◽  
Breast Cancers ◽  
Pathological Features ◽  
Breast Cancer Patients ◽  
Hiv Status ◽  
Receptor Status ◽  
Significant Difference

Abstract Background To characterize the clinico-pathological features including estrogen receptor (ER), progesterone receptor (PR) and Her-2/neu (HER2) expression in breast cancers in Botswana, and to compare them by HIV status. Methods This was a retrospective study using data from the National Health Laboratory and Diagnofirm Medical Laboratory in Gaborone from January 1, 2011 to December 31, 2015. Clinico-pathological details of patients were abstracted from electronic medical records. Results A total of 384 unique breast cancer reports met our inclusion criteria. Of the patients with known HIV status, 42.7% (50/117) were HIV-infected. Median age at the time of breast cancer diagnosis was 54 years (IQR 44–66 years). HIV-infected individuals were more likely to be diagnosed before age 50 years compared to HIV-uninfected individuals (68.2% vs 23.8%, p < 0.001). The majority of patients (68.6%, 35/51) presented with stage III at diagnosis. Stage IV disease was not presented because of the lack of data in pathology records surveyed, and additionally these patients may not present to clinic if the disease is advanced. Overall, 68.9% (151/219) of tumors were ER+ or PR+ and 16.0% (35/219) were HER2+. ER+ or PR+ or both, and HER2- was the most prevalent profile (62.6%, 132/211), followed by triple negative (ER−/PR−/HER2-, 21.3%, 45/211), ER+ or PR+ or both, and HER2+, (9.0%, 19/211) and ER−/PR−/HER2+ (7.1%, 15/211). There was no significant difference in receptor status noted between HIV-infected and HIV-uninfected individuals. Conclusions Majority of breast cancer patients in Botswana present with advanced disease (stage III) at diagnosis and hormone receptor positive disease. HIV-infected breast cancer patients tended to present at a younger age compared to HIV-uninfected patients. HIV status does not appear to be associated with the distribution of receptor status in breast cancers in Botswana.

Barriers to Clinical Trial Participation by Older Women With Breast Cancer

2003 ◽  
Vol 21 (12) ◽  
pp. 2268-2275 ◽  
Author(s):  
M. Margaret Kemeny ◽  
Bercedis L. Peterson ◽  
Alice B. Kornblith ◽  
Hyman B. Muss ◽  
Judith Wheeler ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Older Women ◽  
Cancer Patients ◽  
Older Patients ◽  
Disease Stage ◽  
Trial Participation ◽  
Breast Cancer Patients ◽  
Retrospective Case ◽  
Younger Patients ◽  
Significant Difference

Purpose: Although 48% of breast cancer patients are 65 years old or older, these older patients are severely underrepresented in breast cancer clinical trials. This study tested whether older patients were offered trials significantly less often than younger patients and whether older patients who were offered trials were more likely to refuse participation than younger patients. Patients and Methods: In 10 Cancer and Leukemia Group B institutions, using a retrospective case-control design, breast cancer patients eligible for an open treatment trial were paired: less than 65 years old and ≥ 65 years old. Each of the 77 pairs were matched by disease stage and treating physician. Patients were interviewed as to their reasons for participating or refusing to participate in a trial. The treating physicians were also given questionnaires about their reasons for offering or not offering a trial. Results: Sixty-eight percent of younger stage II patients were offered a trial compared with 34% of the older patients (P = .0004). In multivariate analyses, disease stage and age remained highly significant in predicting trial offering (P = .0008), when controlling for physical functioning and comorbidity. Of those offered a trial, there was no significant difference in participation between younger (56%) and older (50%) patients (P = .67). Conclusion: In a multivariate analysis including comorbid conditions, age and stage were the only predictors of whether a patient was offered a trial. The greatest impediment to enrolling older women onto trials in the setting of this study was the physicians’ perceptions about age and tolerance of toxicity.

scholarly journals Spectrum of breast cancer patients: twin institutional study

2017 ◽  
Vol 4 (9) ◽  
pp. 3077 ◽  
Author(s):  
Prabhat B. Nichkaode ◽  
Aditya Parakh
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Urban Population ◽  
Disease Stage ◽  
Rural India ◽  
Breast Cancer Patients ◽  
Female Population ◽  
Receptor Status ◽  
Common Cancer ◽  
Study Results

Background: Breast cancer is emerging as one of the most common cancer occurring in urban female population of India. It has become the second most common cancer in rural India, after cancer of uterine cervix. One must understand the diversity of presentation of breast cancer patients in the rural and urban population. Author is a surgeon working in a hospital which caters health care to both, rural as well as urban population. The present study is meant to review the data of various types of presentation, of cancer breast in two Institutes in different states. We also would like to compare our data with a few major cancer centers in metropolitan cities. The aim of the study was to present a data of patients with breast cancer at two institutes.Methods: This is a retrospective observational study carried out at two different medical teaching Institutes, CCM Medical College, Kachandur, Durg, Chhattisgarh and other at NKP Salve Institute of Medical Sciences Nagpur, Maharashtra. Study was carried out from 2009 till 2016 and total of 167 patients were included in the study. Data like age, menstrual status, size of lump, stage of disease, grade of disease (Bloom Richardson Elliston Index) and ER, PR, HER/neu receptor status of tumor, presence or absence of metastasis, and follow up records related to outcome, are presented in this study. Results: Out of 167 patients included in the study, two patients were males, and were excluded from our study. It becomes a study of 165 patients. Average age of patients at presentation was between 35 to 65 years. Majority of patients belong to stage III a (bulky operable disease) or III b, (locally advanced breast cancer) Stage II, and stage IV -metastatic disease. No patient of stage I disease reported in the present study. Most common pathological type was infiltrating ductal carcinoma.Conclusions: Breast cancer has emerged as the commonest cancer in urban India, with second most common cancer in rural India. Majority of our patients present with advanced disease stage with numerous poor prognostic factors such as young age, larger tumor size, lymph node metastasis, high pathological grade and poor hormone receptor status. These factors are a reflection of poor health awareness for breast cancer, general indifference towards women’s health, poor financial resources, unavailability of multimodality treatment facilities.

scholarly journals Effect of Low-Level Laser Therapy in Treatment of Chemotherapy Induced Oral Mucositis

2019 ◽  
Vol 10 (2) ◽  
pp. 125-130
Author(s):  
Soheir Shehata Rezk-Allah ◽  
Heba Mohamed Abd Elshafi ◽  
Reem Jan Farid ◽  
Mohamed Abd Elrahman Hassan ◽  
Samy A. Alsirafy
Keyword(s):  
Breast Cancer ◽  
Head And Neck ◽  
Cancer Patients ◽  
Laser Therapy ◽  
Oral Mucositis ◽  
Low Level Laser Therapy ◽  
Breast Cancer Patients ◽  
Low Level Laser ◽  
Level Laser ◽  
Tnf Α

Introduction: Oral mucositis (OM) is an unavoidable condition of the oral cavity that accompanies chemotherapy for various malignant cases. Chemotherapy-induced oral Mucositis (COM) is a frequent complication due to mucotoxic drugs and is known to deteriorate the general health significantly, while negatively affecting the quality of life (QOL). Studies have reported that low-level laser therapy (LLLT) promotes the tissue healing. The objective of the present study was to explore the efficacy of gallium-arsenide (GaAs) laser in treating COM and its impact on inflammatory cytokine levels in patients receiving chemotherapy for various malignancies. Methods: A total of 80 patients with COM received LLLT 6 days/week. OM was graded according to the World Health Organization (WHO) grading scale. The outcome parameters were the serum levels of tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) measured before, during and after administration of LLLT. Results: After LLLT, a significant decrease was found in the mean values of mucositis grade from 2.35 ± 0.695 to 1.13 ± 0.333 after (P < 0.001). A significant reduction in the level of TNF-α was found after LLLT among breast cancer patients (P = 0.0045), but not in head and neck cancer and lymphoma patients. A significant reduction was also found in IL-6 level after treatment among head and neck and breast cancer patients (P = 0.0307 and 0.019, respectively). Conclusion: The use of GaAs LLLT in treating COM in patients with various malignancies is well tolerated by patients, it results in improvement of mucositis, however; mechanism of action does not seem to be completely linked to the change of pro or anti-inflammatory cytokines.

Sign in / Sign up

Export Citation Format

Share Document